BPA
UNCY icon

Beacon Pointe Advisors’s Unicycive Therapeutics UNCY Stock Holding History

Beacon Pointe Advisors’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,186
Closed -$10.2K – 1397
2023
Q3 		$10.2K Buy
+1,186
New +$11.1K ﹤0.01% 1327

Other funds holding UNCY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Beacon Pointe Advisors's UNCY Position: Q4 2023 in Review

Beacon Pointe Advisors sold out of Unicycive Therapeutics (UNCY) in Q4 2023, closing a stake of 1,186 shares — an estimated $10.2K sold.

Beacon Pointe Advisors first reported a position in UNCY in Q3 2023 and held it in 1 quarter. The position peaked at $10.2K in Q3 2023. 16 funds tracked by Wall St. Rank hold UNCY as of Q4 2023.

  • Beacon Pointe Advisors reported no remaining Unicycive Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Beacon Pointe Advisors sold 1,186 Unicycive Therapeutics shares in Q4 2023, an estimated $10.2K.
  • Beacon Pointe Advisors first reported a position in Unicycive Therapeutics in Q3 2023 and held it in 1 quarter.
  • Beacon Pointe Advisors's Unicycive Therapeutics position peaked at $10.2K in Q3 2023.
  • 16 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q4 2023.

Based on Beacon Pointe Advisors's 13F filing for Q4 2023, filed 8 Feb 2024.